← boardnext 2026-12next 2027-09-30
CNTA
Centessa Pharmaceuticals (UK) Limiteddistress 4/10 · elevated risk$40.500%today0% from 52w high
Oncology 1
Lead: Narcolepsy Type 1 · target Orexin-2
Revenue
pre-revenue
Liquidity
$277M
Runway
1.3 yrs
Shares 1y
+15%
Price & events
+64.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.8%
1W
+1.9%
1M
+41.1%
3M
+63.4%
6M
+208.5%
1Y
—
2Y
—
5Y
+131.4%
All
Overview
- Market Cap
- $6.27B
- Enterprise Value
- $6.31B
- Volume
- 0
- 52 Week Range
- $12.43 – $40.50
- Total Shares
- 154.73M
- Float Shares
- 92.48M
- Short %
- 1.22%
- % Held by Insiders
- 0.67%
- % Held by Institutions
- 96.93%
- Beta
- 1.12
Pipeline stages · 4 programs
ORX750
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
cleminorexton
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
LB101
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
ORX142 Tablets
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 5 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12 Estimated 50% readout ~2027-01-15 | Phase 2 | ORX750 | Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia | — | recruiting |
| 2027-09-30 Estimated 50% readout ~2027-12-14 | Phase 2/3 | cleminorexton | Narcolepsy Type 1, Narcolepsy Type 2 | — | recruiting |
| 2026-06-15 | Phase 1 | ORX142 Tablets | Excessive Daytime Sleepiness | 208 | recruiting |
| 2026-04-30 | Phase 2 | ORX750, ORX750, ORX750 | Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia | 90 | recruiting |
| 2025-01-24 | Phase 1/2 | LB101 | Advanced Solid Tumor | 25 | terminated |
Catalyst news & presentations · 7
- 2026-08-11earningsEarningsEarnings releaseyahoo
- 2026-06-24partnershipAcquisition by Eli Lilly completed.SEC 8-K
- 2026-05-21partnershipHSR waiting period expired for acquisition by Eli Lilly.SEC 8-K
- 2026-03-31partnershipCentessa Pharmaceuticals entered into a definitive agreement to be acquired by Eli Lilly for $38 per share plus contingent value rights.SEC 8-K
- Q1 2026trial initiationsecondaryPhase 3ORX750 · Initiate registrational programSEC 8-K
- 2025-11-24partnershipEntered into amended and restated sales agreement with Leerink for at-the-market offering of up to $250M.SEC 8-K
- 2025-06-16fda agreementORX142 · FDA cleared IND for Phase 1 study in healthy volunteers for select neurological and neurodegenerative disordersSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
hold · target $40 (-1% upside) · 4 analysts
- 2026-04-20Wells FargoOverweight → Equal-Weight
- 2026-04-02GuggenheimBuy → Neutral
- 2026-04-01Leerink PartnersOutperform → Market Perform
- 2026-03-31Wolfe ResearchOutperform → Peer Perform
- 2026-03-31NeedhamBuy → Hold
- 2026-02-24Wolfe ResearchOutperform
Competitors — Orexin-2
- none identified
Recent news
- 2026-07-22Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders - Eli Lilly and Company
- 2026-07-17Precision Trading with Centessa Pharmaceuticals Plc (CNTA) Risk Zones - Stock Traders Daily
- 2026-07-08FMR LLC reports 1,800 Centessa shares (NASDAQ: CNTA) - Stock Titan
- 2026-07-06Centessa Pharmaceuticals plc SEC Filing (Jul 6, 2026) - Stock Titan
- 2026-07-02Price to sales forward of Centessa Pharmaceuticals PLC ADR – MUN:260 - TradingView
- 2026-07-01Price to earnings forward of Centessa Pharmaceuticals PLC ADR – MUN:260 - TradingView
- 2026-06-26Centessa Pharmaceuticals (CNTA) holders exit after Eli Lilly acquisition closes - Stock Titan
- 2026-06-24Centessa Pharmaceuticals (CNTA) holders get $38 cash plus CVR in Eli Lilly buyout - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.